HIV entry and membrane lipid rafts

Cholesterol lowering drugs could be used to disrupt the cell entry mechanism of many intracellular pathogens.

Written byTabitha Powledge
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

That assembly and release of HIV-1 particles takes place at the plasma membrane has been established for some time. It has also been suspected that the process additionally requires lipid rafts — plasma membrane domains that serve as docking sites for some proteins involved in signal transduction. In 20 November Proceedings of the National Academy of Sciences, Akira Ono and Eric Freed at the National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Molecular Microbiology, have shown not only that the viral Gag protein, which promotes particle production, associates with lipid rafts, but also that the protein's N terminus and the Gag-Gag interaction domains are crucial for the association (Proc Natl Acad Sci USA 2001, 98:13925-13930).

This has increased speculation that cholesterol-depleting drugs might suppress HIV replication in people. Rafts are rich in cholesterol as well as sphingolipids. James Hildreth, Associate Professor of Pharmacology and Molecular Science, along with ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies